The HR status is often not a primary concern for the treatment of HER2-enriched BC as the current standard of care [taxane plus trastuzumab plus pertuzumab (THP)] is clinically active in both HR+ and HR− subgroups (6, 7). The gene discussed is ERBB2; the disease is breast cancer.